Persistent low-level HIV-1 RNA between 20 and 50 copies/ML in antiretroviral-treated patients: Associated factors and virological outcome

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2231-2235

  Charpentier, Charlotte ^a   Landman, Roland ^a   Laouénan, Cédric ^a   Joly, Véronique ^a   Hamet, Gwenn ^a   Damond, Florence ^a   Brun Vézinet, Françoise ^a   Mentré, France ^a   Descamps, Diane ^a   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

HIV; Low level viraemia; Viral load assay

Indexed keywords

ANTIRETROVIRUS AGENT; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERSISTENT LOW LEVEL VIREMIA; VIREMIA;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLASMA; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865395805     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks191     Document Type: Article

References (15)

1. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
2. Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105: 3879-84.
3. Hatano H, Delwart EL, Norris PJ et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010; 24: 2535-9.
4. Bonora S, Nicastri E, Calcagno A et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81: 400-5.
5. Haïm-Boukobza S, Morand-Joubert L, Flandre P et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25: 341-4.
6. Palmisano L, Giuliano M, Nicastri E et al. Residual viraemia in subjects with chronic HIV infection and viral load,50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005; 19: 1843-7.
7. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
8. Pascual-Pareja JF, Martínez-Prats L, Luczkowiak J et al. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy. J Clin Microbiol 2010; 48: 1911-2.
9. Richman DD, Margolis DM, Delaney M et al. The challenge of finding a cure for HIV infection. Science 2009; 323: 1304-7.
10. Montaner JS, Richman DD, Hammer SM. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis 2009; 49: 1283-4.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (16 November 2011, date last accessed).
12. Widdrington J, Payne B, Medhi M et al. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62: 87-92.
13. Maggiolo F, Callegaro A, Cologni G et al. Residual low-level HIV viremia in HAART-treated patients and risk of virological failure: a new standard of care? In: Abstracts of the Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011. Abstract TULBPE030.
14. Nettles RE, Kieffer TL, Kwon P et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-29.
15. Taiwo B, Gallien S, Aga E et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 2011; 204: 515-20.